Guided Therapeutics, Inc.
GTHP
$0.20
-$0.03-12.28%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 76,600.00% | 10,857.14% | 368.42% | 210.53% | -98.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76,600.00% | 10,857.14% | 368.42% | 210.53% | -98.78% |
| Cost of Revenue | 6,400.00% | 3,800.00% | 266.67% | 86.36% | -94.55% |
| Gross Profit | 28,700.00% | 28,500.00% | 460.00% | 381.25% | -107.41% |
| SG&A Expenses | 78.23% | 73.26% | 110.30% | 95.39% | -18.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.30% | 61.12% | 74.71% | 68.22% | -6.47% |
| Operating Income | -16.93% | -25.29% | -66.26% | -64.30% | 3.08% |
| Income Before Tax | -33.95% | -32.31% | -22.36% | -17.02% | 19.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.95% | -32.31% | -22.36% | -17.02% | 19.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.95% | -32.31% | -22.36% | -17.02% | 19.19% |
| EBIT | -16.93% | -25.29% | -66.26% | -64.30% | 3.08% |
| EBITDA | -16.96% | -25.35% | -66.72% | -64.73% | 3.09% |
| EPS Basic | -6.39% | 6.87% | 9.15% | 7.21% | 29.81% |
| Normalized Basic EPS | 7.31% | 9.63% | -26.29% | -31.18% | 12.75% |
| EPS Diluted | 14.39% | 16.94% | -12.81% | -12.96% | 14.62% |
| Normalized Diluted EPS | 7.31% | 9.63% | -26.29% | -31.18% | 12.75% |
| Average Basic Shares Outstanding | 37.50% | 36.66% | 31.67% | 23.62% | 15.69% |
| Average Diluted Shares Outstanding | 37.50% | 36.66% | 31.67% | 23.62% | 15.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |